prostate cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All patients had a histologically confirmed daignosis of prostate cancer Patients charactaristics. The treatment for prostate cancer is medication or radiation, not radical prostatectomy. The presence or absence of distant metastasis are not matter. Demonstrated evidence of recurrent prostatic cancer refractory to standard hormonal and anti cancer agnet therapy, including one or more hormonal drug, docetaxel, was required. Other eligibility criteria included the following: age over 20, under 80 years; Eastern Cooperative Oncology Group (EOCGI) performance status 0 to 2;
Exclusion criteria
Exclusion criteria: Exclusion criteria included the following: the patients who received radical prostatectomy; Case with metal reacting to the magnetic field in the body (Pacemaker, implant denture, iron clip bolt); patients with pleural effusion, ascitic fluid, the pericardial effusion which need urgent treatment; patients with active infection; patients with the multiple primary cancer with less than five years in disease-free interval; patients who communication is not possible; patients who is not suitable for local anesthesia; patients who has circulatory; during anticoagulation; patients of the diabetes mellitus inadequate control; the case that a chief physician judged to be unsuitable for subject of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequencies of adverse events grade 3 or more of CTCAE v4.0 Adverse events are evaluated at just after, 12 hours later, 24 hours later, one week later and on month later of injection of magnetite | — |
Countries
Japan
Contacts
Nagoya City University Graduate School of Medical Sciences Department of Nephro-urology